---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027440"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:50:02.242034+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q2 revenue $0.5M, net operating loss $8.3M; appoints James Liu interim CFO

## Summary
- Revenue $0.5M, cost of revenue $0.2M; net operating loss $8.3M vs $8.6M YoY, down $0.3M.
- Cash, equivalents, and marketable securities $17.9M at June 30; avg cash burn below $5M/qtr in 2H 2023.
- R&D expense down 56% YoY to $2.4M; G&A down 36% to $3.5M; S&M down 77% to $0.8M.
- Transplant product launch on track for Q4 early access; MolDX coverage reviews ongoing.
- James Liu (age 28) promoted to Sr. Director, Controller & PAO; appointed interim Principal Financial Officer; salary $200K, target bonus 35%.

## SEC filing metadata
- accession: 0001493152-23-027440
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223027440/0001493152-23-027440-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223027440/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027440
- JSON: https://secwatch.observer/filing/0001493152-23-027440.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027440.txt

## Key facts
- Earnings Releases
  Insight Molecular Diagnostics Inc. reported Second Quarter 2023 results: revenue 0.5 million.
  - Period: Second Quarter 2023
  - Revenue: 0.5 million
  - Result: reported results
  source text: Consolidated revenues for the second quarter of 2023 were approximately $0.5 million, and cost of revenues for the second quarter were approximately $0.2 million, primarily from services customers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223027440/0001493152-23-027440-index.htm
- Executive change
  James Liu was appointed as interim Principal Financial Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: interim Principal Financial Officer
  source text: On that same date, the Company appointed Mr. Liu to the additional role of interim Principal Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223027440/0001493152-23-027440-index.htm
- Executive change
  James Liu changed role as Senior Director, Controller & Principal Accounting Officer at Insight Molecular Diagnostics Inc..
  - Action: promoted
  - Role: Senior Director, Controller & Principal Accounting Officer
  source text: On August 4, 2023, the Company promoted James Liu to Senior Director, Controller & Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223027440/0001493152-23-027440-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.